论文部分内容阅读
心房颤动是临床发病率最高的心律失常,可诱发心力衰竭、卒中及外周血管栓塞等致死性心脑血管疾病。随着全球人口老龄化加剧,心房颤动患者逐年增加,造成巨大的社会和经济负担。目前,药物是心房颤动临床治疗的主要手段,然而药物治疗的有效率低,并存在致心律失常的风险。近年来,非编码核糖核酸(RNAs)在个体发育及多种疾病的发生发展中的重要作用日益显现。越来越多研究表明,非编码RNAs与心房颤动的发生和维持密切相关。阐明非编码RNAs在心房颤动中的作用及调控机制,建立心房颤动相关非编码RNAs交互网络,对临床早期预测患者心房颤动易感性,发现新的药物治疗靶点及评估患者预后情况具有重要意义。本文综述非编码RNAs在心房颤动研究中的新进展。
Atrial fibrillation is the highest incidence of clinical arrhythmias, can induce heart failure, stroke and peripheral vascular embolism and other fatal cardiovascular and cerebrovascular diseases. As the global population ages, the number of patients with atrial fibrillation increases year by year, creating a huge social and economic burden. At present, the drug is the main means of clinical treatment of atrial fibrillation, however, the effectiveness of the drug treatment is low and there is a risk of arrhythmia. In recent years, non-coding RNAs (RNAs) play an increasingly important role in the development of individuals and the development of various diseases. More and more studies have shown that non-coding RNAs and the occurrence and maintenance of atrial fibrillation are closely related. To elucidate the role and regulation of non-coding RNAs in atrial fibrillation and to establish a non-coding RNAs network for atrial fibrillation, it is of great significance to predict the predisposition of patients with atrial fibrillation in the early stage and to find new therapeutic targets and to evaluate the prognosis of patients . This article reviews the recent advances in the study of non-coding RNAs in atrial fibrillation.